Alaxia is a French private biotech company developing therapeutic solutions for respiratory diseases based on its proprietary peroxidase platform. The most advanced drug candidate, ALX-009, is an antimicrobial innovative compound aiming at treating cystic fibrosis, including the most resistant bacterial strains.
ALX-009 Cystic Fibrosis
First-in-class orphan drug.
Targets multi-drug-resistant (MDR) bacterial infections not treatable by current antibiotic therapies.
Ready-to-inhale combination of two endogenous substances contribution to the innate immune system response. Innovative mode of action: Activity unaffected by CF patient’s sputum and no emergence of bacterial resistance.